1. Sung, H.; Ferlay, J.; Siegel, R. L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021, 71, 209-249.

2. Siegel, R. L.; Miller, K. D.; Fuchs, H. E.; Jemal, A. Cancer Statistics, 2022. *CA Cancer J Clin.* 2022, 72, 7-33.

3. Mondal, J.; Panigrahi, A. K.; Khuda-Bukhsh, A. R. Conventional Chemotherapy: Problems and Scope for Combined Therapies with Certain Herbal Products and Dietary Supplements. *Austin J Mol Cell Biol.* 2014, 1, 10.

4. Carvalho, A.; Fernandes, A. R.; Baptista, P. V. Chapter 10 - Nanoparticles as Delivery Systems in Cancer Therapy: Focus on Gold Nanoparticles and Drugs. In *Applications of Targeted Nano Drugs and Delivery Systems*, Mohapatra, S. S.; Ranjan, S.; Dasgupta, N.; Mishra, R. K.; Thomas, S., eds.; Elsevier: 2019; pp 257-295.

5. Chidambaram, M.; Manavalan, R.; Kathiresan, K. Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations. *J Pharm Pharm Sci.* 2011, 14, 67-77.

6. Choi, C. H. ABC Transporters as Multidrug Resistance Mechanisms and the Development of Chemosensitizers for Their Reversal. *Cancer Cell Int.* 2005, 5, 30.

7. Rahman, M. M.; McFadden, G. Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy. *Cancers (Basel).* 2021, 13, 5452.

8. Truong, C. S.; Yoo, S. Y. Oncolytic Vaccinia Virus in Lung Cancer Vaccines. *Vaccines.* 2022, 10, 240.

9. Tian, Y.; Xie, D.; Yang, L. Engineering Strategies to Enhance Oncolytic Viruses in Cancer Immunotherapy. *Signal Transduct Target Ther.* 2022, 7, 117.

10. Lemos de Matos, A.; Franco, L. S.; McFadden, G. Oncolytic Viruses and the Immune System: The Dynamic Duo. *Mol Ther Methods Clin Dev.* 2020, 17, 349-358.

11. Filley, A. C.; Dey, M. Immune System, Friend or Foe of Oncolytic Virotherapy? *Front Oncol.* 2017, 7, 106.

12. Maroun, J.; Muñoz-Alía, M.; Ammayappan, A.; Schulze, A.; Peng, K. W.; Russell, S. Designing and Building Oncolytic Viruses. *Future Virol.* 2017, 12, 193-213.

13. Jin, K. T.; Du, W. L.; Liu, Y. Y.; Lan, H. R.; Si, J. X.; Mou, X. Z. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements. *Cancers (Basel).* 2021, 13, 588.

14. Kaufman, H. L.; Kohlhapp, F. J.; Zloza, A. Oncolytic Viruses: A New Class of Immunotherapy Drugs. *Nat Rev Drug Discov.* 2015, 14, 642-662.

15. Martini, V.; D’Avanzo, F.; Maggiora, P. M.; Varughese, F. M.; Sica, A.; Gennari, A. Oncolytic Virotherapy: New Weapon for Breast Cancer Treatment. *Ecancermedicalscience.* 2020, 14, 1149.

16. You, Z.; Fischer, D. C.; Tong, X.; Hasenburg, A.; Aguilar-Cordova, E.; Kieback, D. G. Coxsackievirus-Adenovirus Receptor Expression in Ovarian Cancer Cell Lines Is Associated with Increased Adenovirus Transduction Efficiency and Transgene Expression. *Cancer Gene Ther.* 2001, 8, 168-175.

17. Hensen, L. C. M.; Hoeben, R. C.; Bots, S. T. F. Adenovirus Receptor Expression in Cancer and Its Multifaceted Role in Oncolytic Adenovirus Therapy. *Int J Mol Sci.* 2020, 21, 6828.

18. Cheng, T.; Bai, J.; Chung, C. S.; Chen, Y.; Fallon, E. A.; Ayala, A. Herpes Virus Entry Mediator (HVEM) Expression Promotes Inflammation/Organ Injury in Response to Experimental Indirect-Acute Lung Injury. *Shock.* 2019, 51, 487-494.

19. Tang, M.; Cao, X.; Li, Y.; Li, G. Q.; He, Q. H.; Li, S. J.; Chen, J.; Xu, G. L.; Zhang, K. Q. High Expression of Herpes Virus Entry Mediator Is Associated with Poor Prognosis in Clear Cell Renal Cell Carcinoma. *Am J Cancer Res.* 2019, 9, 975-987.

20. Ferreira, T.; Kulkarni, A.; Bretscher, C.; Richter, K.; Ehrlich, M.; Marchini, A. Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis. *Viruses.* 2020, 12, 1199.

21. Nettelbeck, D. M.; Leber, M. F.; Altomonte, J.; Angelova, A.; Beil, J.; Berchtold, S.; Delic, M.; Eberle, J.; Ehrhardt, A.; Engeland, C. E.; Fechner, H.; Geletneky, K.; Goepfert, K.; Holm, P. S.; Kochanek, S.; Kreppel, F.; Krutzke, L.; Kühnel, F.; Lang, K. S.; Marchini, A.; Moehler, M.; Mühlebach, M. D.; Naumann, U.; Nawroth, R.; Nüesch, J.; Rommelaere, J.; Lauer, U. M.; Ungerechts, G. Virotherapy in Germany—Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies. *Viruses.* 2021, 13, 1420.

22. Ferreira, T.; Kulkarni, A.; Bretscher, C.; Nazarov, P. V.; Hossain, J. A.; Ystaas, L. A. R.; Miletic, H.; Röth, R.; Niesler, B.; Marchini, A. Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells. *Viruses.* 2022, 14, 1018.

23. Bretscher, C.; Marchini, A. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future. *Viruses.* 2019, 11, 562.

24. Marchini, A.; Bonifati, S.; Scott, E. M.; Angelova, A. L.; Rommelaere, J. Oncolytic Parvoviruses: From Basic Virology to Clinical Applications. *Virol J.* 2015, 12, 6.

25. Bradley, S.; Jakes, A. D.; Harrington, K.; Pandha, H.; Melcher, A.; Errington-Mais, F. Applications of Coxsackievirus A21 in Oncology. *Oncolytic Virother.* 2014, 3, 47-55.

26. Au, G. G.; Lincz, L. F.; Enno, A.; Shafren, D. R. Oncolytic Coxsackievirus A21 as a Novel Therapy for Multiple Myeloma. *Br J Haematol.* 2007, 137, 133-141.

27. Li, Y. C.; Zhou, Q.; Song, Q. K.; Wang, R. B.; Lyu, S.; Guan, X.; Zhao, Y. J.; Wu, J. P. Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study. *J Immunol Res.* 2020, 2020, 3948928.

28. Lupo, K. B.; Matosevic, S. CD155 Immunoregulation as a Target for Natural Killer Cell Immunotherapy in Glioblastoma. *J Hematol Oncol.* 2020, 13, 76.

29. Masson, D.; Jarry, A.; Baury, B.; Blanchardie, P.; Laboisse, C.; Lustenberger, P.; Denis, M. G. Overexpression of the CD155 Gene in Human Colorectal Carcinoma. *Gut.* 2001, 49, 236-240.

30. Huang, D. W.; Huang, M.; Lin, X. S.; Huang, Q. CD155 Expression and Its Correlation with Clinicopathologic Characteristics, Angiogenesis, and Prognosis in Human Cholangiocarcinoma. *Onco Targets Ther.* 2017, 10, 3817-3825.

31. Elvington, M.; Liszewski, M. K.; Atkinson, J. P. CD46 and Oncologic Interactions: Friendly Fire Against Cancer. *Antibodies (Basel).* 2020, 9, 59.

32. Russell, L.; Peng, K. W. The Emerging Role of Oncolytic Virus Therapy Against Cancer. *Chin Clin Oncol.* 2018, 7, 16.

33. Nikolic, J.; Belot, L.; Raux, H.; Legrand, P.; Gaudin, Y.; A, A. A. Structural Basis for the Recognition of LDL-Receptor Family Members by VSV Glycoprotein. *Nat Commun.* 2018, 9, 1029.

34. Zhang, Y.; Nagalo, B. M. Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We? *Front Immunol.* 2022, 13, 898631.

35. Martignone, S.; Ménard, S.; Bufalino, R.; Cascinelli, N.; Pellegrini, R.; Tagliabue, E.; Andreola, S.; Rilke, F.; Colnaghi, M. I. Prognostic Significance of the 67-Kilodalton Laminin Receptor Expression in Human Breast Carcinomas. *J Natl Cancer Inst.* 1993, 85, 398-402.

36. Fontanini, G.; Vignati, S.; Chiné, S.; Lucchi, M.; Mussi, A.; Angeletti, C. A.; Ménard, S.; Castronovo, V.; Bevilacqua, G. 67-Kilodalton Laminin Receptor Expression Correlates with Worse Prognostic Indicators in Non-Small Cell Lung Carcinomas. *Clin Cancer Res.* 1997, 3, 227-231.

37. Sanjuán, X.; Fernández, P. L.; Miquel, R.; Muñoz, J.; Castronovo, V.; Ménard, S.; Palacín, A.; Cardesa, A.; Campo, E. Overexpression of the 67-kD Laminin Receptor Correlates with Tumor Progression in Human Colorectal Carcinoma. *J Pathol.* 1996, 179, 376-380.

38. Taraboletti, G.; Belotti, D.; Giavazzi, R.; Sobel, M. E.; Castronovo, V. Enhancement of Metastatic Potential of Murine and Human Melanoma Cells by Laminin Receptor Peptide G: Attachment of Cancer Cells to Subendothelial Matrix as a Pathway for Hematogenous Metastasis. *J Natl Cancer Inst.* 1993, 85, 235-240.

39. van den Brule, F. A.; Buicu, C.; Berchuck, A.; Bast, R. C.; Deprez, M.; Liu, F. T.; Cooper, D. N.; Pieters, C.; Sobel, M. E.; Castronovo, V. Expression of the 67-kD Laminin Receptor, Galectin-1, and Galectin-3 in Advanced Human Uterine Adenocarcinoma. *Hum Pathol.* 1996, 27, 1185-1191.

40. Xing, L.; Huhtala, M.; Pietiäinen, V.; Käpylä, J.; Vuorinen, K.; Marjomäki, V.; Heino, J.; Johnson, M. S.; Hyypiä, T.; Cheng, R. H. Structural and Functional Analysis of Integrin Alpha2I Domain Interaction with Echovirus 1. *J Biol Chem.* 2004, 279, 11632-11638.

41. Haley, E. S.; Au, G. G.; Carlton, B. R.; Barry, R. D.; Shafren, D. R. Regional Administration of Oncolytic Echovirus 1 as a Novel Therapy for the Peritoneal Dissemination of Gastric Cancer. *J Mol Med (Berl).* 2009, 87, 385-399.

42. García-Romero, N.; Palacín-Aliana, I.; Esteban-Rubio, S.; Madurga, R.; Rius-Rocabert, S.; Carrión-Navarro, J.; Presa, J.; Cuadrado-Castano, S.; Sánchez-Gómez, P.; García-Sastre, A.; Nistal-Villan, E.; Ayuso-Sacido, A. Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion. *Cells.* 2020, 9, 1405.

43. Keshavarz, M.; Nejad, A. S. M.; Esghaei, M.; Bokharaei-Salim, F.; Dianat-Moghadam, H.; Keyvani, H.; Ghaemi, A. Oncolytic Newcastle Disease Virus Reduces Growth of Cervical Cancer Cell by Inducing Apoptosis. *Saudi J Biol Sci.* 2020, 27, 47-52.

44. Yuan, P.; Swanson, K. A.; Leser, G. P.; Paterson, R. G.; Lamb, R. A.; Jardetzky, T. S. Structure of the Newcastle Disease Virus Hemagglutinin-Neuraminidase (HN) Ectodomain Reveals a Four-Helix Bundle Stalk. *Proc Natl Acad Sci U S A.* 2011, 108, 14920-14925.

45. Chu, Z.; Gao, X.; Liu, H.; Ma, J.; Wang, C.; Lu, K.; Han, Q.; Wang, Y.; Wang, C.; Adam, F. E. A.; Wang, X.; Xiao, S.; Yang, Z. Newcastle Disease Virus Selectively Infects Dividing Cells and Promotes Viral Proliferation. *Vet Res.* 2019, 50, 27.

46. Jhawar, S. R.; Thandoni, A.; Bommareddy, P. K.; Hassan, S.; Kohlhapp, F. J.; Goyal, S.; Schenkel, J. M.; Silk, A. W.; Zloza, A. Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies. *Front Oncol.* 2017, 7, 202.

47. Katze, M. G.; He, Y.; Gale, M., Jr. Viruses and Interferon: A Fight for Supremacy. *Nat Rev Immunol.* 2002, 2, 675-687.

48. Santos Apolonio, J.; Lima de Souza Gonçalves, V.; Cordeiro Santos, M. L.; Silva Luz, M.; Silva Souza, J. V.; Rocha Pinheiro, S. L.; de Souza, W. R.; Sande Loureiro, M.; de Melo, F. F. Oncolytic Virus Therapy in Cancer: A Current Review. *World J Virol.* 2021, 10, 229-255.

49. Samuel, C. E. Antiviral Actions of Interferons. *Clin Microbiol Rev.* 2001, 14, 778-809, table of contents.

50. Fernandes, J. Oncogenes: The Passport for Viral Oncolysis through PKR Inhibition. *Biomark Cancer.* 2016, 8, 101-110.

51. Balachandran, S.; Kim, C. N.; Yeh, W. C.; Mak, T. W.; Bhalla, K.; Barber, G. N. Activation of the dsRNA-Dependent Protein Kinase, PKR, Induces Apoptosis through FADD-Mediated Death Signaling. *EMBO J.* 1998, 17, 6888-6902.

52. Nakayama, Y.; Plisch, E. H.; Sullivan, J.; Thomas, C.; Czuprynski, C. J.; Williams, B. R.; Suresh, M. Role of PKR and Type I IFNs in Viral Control During Primary and Secondary Infection. *PLoS Pathog.* 2010, 6, e1000966.

53. Cook, M.; Chauhan, A. Clinical Application of Oncolytic Viruses: A Systematic Review. *Int J Mol Sci.* 2020, 21, 7505.

54. Ahlander, J.; Bosco, G. The RB/E2F Pathway and Regulation of RNA Processing. *Biochem Biophys Res Commun.* 2009, 384, 280-283.

55. Topacio, B. R.; Zatulovskiy, E.; Cristea, S.; Xie, S.; Tambo, C. S.; Rubin, S. M.; Sage, J.; Kõivomägi, M.; Skotheim, J. M. Cyclin D-Cdk4,6 Drives Cell-Cycle Progression via the Retinoblastoma Protein’s C-Terminal Helix. *Mol Cell.* 2019, 74, 758-770.e4.

56. Fernández-Medarde, A.; Santos, E. Ras in Cancer and Developmental Diseases. *Genes Cancer.* 2011, 2, 344-358.

57. Mansour, M.; Palese, P.; Zamarin, D. Oncolytic Specificity of Newcastle Disease Virus Is Mediated by Selectivity for Apoptosis-Resistant Cells. *J Virol.* 2011, 85, 6015-6023.

58. Aurelian, L. Oncolytic Viruses as Immunotherapy: Progress and Remaining Challenges. *Onco Targets Ther.* 2016, 9, 2627-2637.

59. Chiocca, E. A.; Rabkin, S. D. Oncolytic Viruses and Their Application to Cancer Immunotherapy. *Cancer Immunol Res.* 2014, 2, 295-300.

60. Bommareddy, P. K.; Shettigar, M.; Kaufman, H. L. Integrating Oncolytic Viruses in Combination Cancer Immunotherapy. *Nat Rev Immunol.* 2018, 18, 498-513.

61. Lawler, S. E.; Speranza, M. C.; Cho, C. F.; Chiocca, E. A. Oncolytic Viruses in Cancer Treatment: A Review. *JAMA Oncol.* 2017, 3, 841-849.

62. Fukuhara, H.; Ino, Y.; Todo, T. Oncolytic Virus Therapy: A New Era of Cancer Treatment at Dawn. *Cancer Sci.* 2016, 107, 1373-1379.

63. Uchihashi, T.; Nakahara, H.; Fukuhara, H.; Iwai, M.; Ito, H.; Sugauchi, A.; Tanaka, M.; Kogo, M.; Todo, T. Oncolytic Herpes Virus G47Δ Injected into Tongue Cancer Swiftly Traffics in Lymphatics and Suppresses Metastasis. *Mol Ther Oncolytics.* 2021, 22, 388-398.

64. Woller, N.; Gürlevik, E.; Ureche, C. I.; Schumacher, A.; Kühnel, F. Oncolytic Viruses as Anticancer Vaccines. *Front Oncol.* 2014, 4, 188.

65. Todo, T.; Martuza, R. L.; Rabkin, S. D.; Johnson, P. A. Oncolytic Herpes Simplex Virus Vector with Enhanced MHC Class I Presentation and Tumor Cell Killing. *Proc Natl Acad Sci U S A.* 2001, 98, 6396-6401.

66. Goldstein, D. J.; Weller, S. K. Herpes Simplex Virus Type 1-Induced Ribonucleotide Reductase Activity Is Dispensable for Virus Growth and DNA Synthesis: Isolation and Characterization of an ICP6 LacZ Insertion Mutant. *J Virol.* 1988, 62, 196-205.

67. Gholami, S.; Marano, A.; Chen, N. G.; Aguilar, R. J.; Frentzen, A.; Chen, C. H.; Lou, E.; Fujisawa, S.; Eveno, C.; Belin, L.; Zanzonico, P.; Szalay, A.; Fong, Y. A Novel Vaccinia Virus with Dual Oncolytic and Anti-Angiogenic Therapeutic Effects against Triple-Negative Breast Cancer. *Breast Cancer Res Treat.* 2014, 148, 489-499.

68. Howells, A.; Marelli, G.; Lemoine, N. R.; Wang, Y. Oncolytic Viruses—Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer. *Front Oncol.* 2017, 7, 195.

69. Bulcha, J. T.; Wang, Y.; Ma, H.; Tai, P. W. L.; Gao, G. Viral Vector Platforms within the Gene Therapy Landscape. *Signal Transduct Target Ther.* 2021, 6, 53.

70. Bezeljak, U. Cancer Gene Therapy Goes Viral: Viral Vector Platforms Come of Age. *Radiol Oncol.* 2022, 56, 1-13.

71. Cross, D.; Burmester, J. K. Gene Therapy for Cancer Treatment: Past, Present and Future. *Clin Med Res.* 2006, 4, 218-227.

72. Ginn, S. L.; Amaya, A. K.; Alexander, I. E.; Edelstein, M.; Abedi, M. R. Gene Therapy Clinical Trials Worldwide to 2017: An Update. *J Gene Med.* 2018, 20, e3015.

73. Miller, K. E.; Cassady, K. A.; Roth, J. C.; Clements, J.; Schieffer, K. M.; Leraas, K.; Miller, A. R.; Prasad, N.; Leavenworth, J. W.; Aban, I. B.; Whitley, R. J.; Gillespie, G. Y.; Mardis, E. R.; Markert, J. M. Immune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study. *Clin Cancer Res.* 2022, 28, 498-506.

74. Cui, C.; Wang, X.; Lian, B.; Ji, Q.; Zhou, L.; Chi, Z.; Si, L.; Sheng, X.; Kong, Y.; Yu, J.; Li, S.; Mao, L.; Tang, B.; Dai, J.; Yan, X.; Bai, X.; Andtbacka, R.; Guo, J. OrienX010, an Oncolytic Virus, in Patients with Unresectable Stage IIIC-IV Melanoma: A Phase Ib Study. *J Immunother Cancer.* 2022, 10, e004307.

75. García, M.; Moreno, R.; Gil-Martin, M.; Cascallò, M.; de Olza, M. O.; Cuadra, C.; Piulats, J. M.; Navarro, V.; Domenech, M.; Alemany, R.; Salazar, R. A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. *Hum Gene Ther.* 2019, 30, 352-364.

76. Lang, F. F.; Conrad, C.; Gomez-Manzano, C.; Yung, W. K. A.; Sawaya, R.; Weinberg, J. S.; Prabhu, S. S.; Rao, G.; Fuller, G. N.; Aldape, K. D.; Gumin, J.; Vence, L. M.; Wistuba, I.; Rodriguez-Canales, J.; Villalobos, P. A.; Dirven, C. M. F.; Tejada, S.; Valle, R. D.; Alonso, M. M.; Ewald, B.; Peterkin, J. J.; Tufaro, F.; Fueyo, J. Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma. *J Clin Oncol.* 2018, 36, 1419-1427.

77. Müller, L. M. E.; Holmes, M.; Michael, J. L.; Scott, G. B.; West, E. J.; Scott, K. J.; Parrish, C.; Hall, K.; Stäble, S.; Jennings, V. A.; Cullen, M.; McConnell, S.; Langton, C.; Tidswell, E. L.; Shafren, D.; Samson, A.; Harrington, K. J.; Pandha, H.; Ralph, C.; Kelly, R. J.; Cook, G.; Melcher, A.; A.; Errington-Mais, F. Plasmacytoid Dendritic Cells Orchestrate Innate and Adaptive Anti-Tumor Immunity Induced by Oncolytic Coxsackievirus A21. *J Immunother Cancer.* 2019, 7, 164.

78. Annels, N. E.; Mansfield, D.; Arif, M.; Ballesteros-Merino, C.; Simpson, G. R.; Denyer, M.; Sandhu, S. S.; Melcher, A. A.; Harrington, K. J.; Davies, B.; Au, G.; Grose, M.; Bagwan, I.; Fox, B.; Vile, R.; Mostafid, H.; Shafren, D.; Pandha, H. S. Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer. *Clin Cancer Res.* 2019, 25, 5818-5831.

79. Dispenzieri, A.; Tong, C.; LaPlant, B.; Lacy, M. Q.; Laumann, K.; Dingli, D.; Zhou, Y.; Federspiel, M. J.; Gertz, M. A.; Hayman, S.; Buadi, F.; O’Connor, M.; Lowe, V. J.; Peng, K. W.; Russell, S. J. Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus Genetically Engineered to Express the Sodium Iodide Symporter in Patients with Recurrent or Refractory Multiple Myeloma. *Leukemia.* 2017, 31, 2791-2798.

80. Beasley, G. M.; Nair, S. K.; Farrow, N. E.; Landa, K.; Selim, M. A.; Wiggs, C. A.; Jung, S. H.; Bigner, D. D.; True Kelly, A.; Gromeier, M.; Salama, A. K. Phase I Trial of Intratumoral PVSRIPO in Patients with Unresectable, Treatment-Refractory Melanoma. *J Immunother Cancer.* 2021, 9, e002203.

81. Beasley, G. M.; Brown, M. C.; Farrow, N. E.; Landa, K.; Al-Rohil, R. N.; Selim, M. A.; Therien, A. D.; Jung, S. H.; Gao, J.; Boczkowski, D.; Holl, E. K.; Salama, A. K. S.; Bigner, D. D.; Gromeier, M.; Nair, S. K. Multimodality Analysis Confers a Prognostic Benefit of a T-Cell Infiltrated Tumor Microenvironment and Peripheral Immune Status in Patients with Melanoma. *J Immunother Cancer.* 2022, 10, e005052.

82. Lauer, U. M.; Schell, M.; Beil, J.; Berchtold, S.; Koppenhöfer, U.; Glatzle, J.; Königsrainer, A.; Möhle, R.; Nann, D.; Fend, F.; Pfannenberg, C.; Bitzer, M.; Malek, N. P. Phase I Study of Oncolytic Vaccinia Virus GL-ONC1 in Patients with Peritoneal Carcinomatosis. *Clin Cancer Res.* 2018, 24, 4388-4398.

83. Minev, B. R.; Lander, E.; Feller, J. F.; Berman, M.; Greenwood, B. M.; Minev, I.; Santidrian, A. F.; Nguyen, D.; Draganov, D.; Killinc, M. O.; Vyalkova, A.; Kesari, S.; McClay, E.; Carabulea, G.; Marincola, F. M.; Butterfield, L. H.; Szalay, A. A. First-in-Human Study of TK-Positive Oncolytic Vaccinia Virus Delivered by Adipose Stromal Vascular Fraction Cells. *J Transl Med.* 2019, 17, 271.

84. Manyam, M.; Stephens, A. J.; Kennard, J. A.; LeBlanc, J.; Ahmad, S.; Kendrick, J. E.; Holloway, R. W. A Phase 1b Study of Intraperitoneal Oncolytic Viral Immunotherapy in Platinum-Resistant or Refractory Ovarian Cancer. *Gynecol Oncol.* 2021, 163, 481-489.

85. Mahalingam, D.; Wilkinson, G. A.; Eng, K. H.; Fields, P.; Raber, P.; Moseley, J. L.; Cheetham, K.; Coffey, M.; Nuovo, G.; Kalinski, P.; Zhang, B.; Arora, S. P.; Fountzilas, C. Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. *Clin Cancer Res.* 2020, 26, 71-81.

86. Parakrama, R.; Fogel, E.; Chandy, C.; Augustine, T.; Coffey, M.; Tesfa, L.; Goel, S.; Maitra, R. Immune Characterization of Metastatic Colorectal Cancer Patients Post Reovirus Administration. *BMC Cancer.* 2020, 20, 569.

87. Geletneky, K.; Hajda, J.; Angelova, A. L.; Leuchs, B.; Capper, D.; Bartsch, A. J.; Neumann, J. O.; Schöning, T.; Hüsing, J.; Beelte, B.; Kiprianova, I.; Roscher, M.; Bhat, R.; von Deimling, A.; Brück, W.; Just, A.; Frehtman, V.; Löbhard, S.; Terletskaia-Ladwig, E.; Fry, J.; Jochims, K.; Daniel, V.; Krebs, O.; Dahm, M.; Huber, B.; Unterberg, A.; Rommelaere, J. Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial. *Mol Ther.* 2017, 25, 2620-2634.

88. Burke, M. J.; Ahern, C.; Weigel, B. J.; Poirier, J. T.; Rudin, C. M.; Chen, Y.; Cripe, T. P.; Bernhardt, M. B.; Blaney, S. M. Phase I Trial of Seneca Valley Virus (NTX-010) in Children with Relapsed/Refractory Solid Tumors: A Report of the Children’s Oncology Group. *Pediatr Blood Cancer.* 2015, 62, 743-750.

89. Zhang, B.; Huang, J.; Tang, J.; Hu, S.; Luo, S.; Luo, Z.; Zhou, F.; Tan, S.; Ying, J.; Chang, Q.; Zhang, R.; Geng, C.; Wu, D.; Gu, X.; Liu, B. Intratumoral OH2, an Oncolytic Herpes Simplex Virus 2, in Patients with Advanced Solid Tumors: A Multicenter, Phase I/II Clinical Trial. *J Immunother Cancer.* 2021, 9, e002224.

90. Todo, T.; Ino, Y.; Ohtsu, H.; Shibahara, J.; Tanaka, M. A Phase I/II Study of Triple-Mutated Oncolytic Herpes Virus G47∆ in Patients with Progressive Glioblastoma. *Nat Commun.* 2022, 13, 4119.

91. Todo, T.; Ito, H.; Ino, Y.; Ohtsu, H.; Ota, Y.; Shibahara, J.; Tanaka, M. Intratumoral Oncolytic Herpes Virus G47∆ for Residual or Recurrent Glioblastoma: A Phase 2 Trial. *Nat Med.* 2022, 28, 1630-1639.

92. Monga, V.; Miller, B. J.; Tanas, M.; Boukhar, S.; Allen, B.; Anderson, C.; Stephens, L.; Hartwig, S.; Varga, S.; Houtman, J.; Wang, L.; Zhang, W.; Jaber, O.; Thomason, J.; Kuehn, D.; Rajput, M.; Metz, C.; Zamba, K. D.; Mott, S.; Abanonu, C.; Bhatia, S.; Milhem, M. Intratumoral Talimogene Laherparepvec Injection with Concurrent Preoperative Radiation in Patients with Locally Advanced Soft-Tissue Sarcoma of the Trunk and Extremities: Phase IB/II Trial. *J Immunother Cancer.* 2021, 9, e003119.

93. Kai, M.; Marx, A. N.; Liu, D. D.; Shen, Y.; Gao, H.; Reuben, J. M.; Whitman, G.; Krishnamurthy, S.; Ross, M. I.; Litton, J. K.; Lim, B.; Ibrahim, N.; Kogawa, T.; Ueno, N. T. A Phase II Study of Talimogene Laherparepvec for Patients with Inoperable Locoregional Recurrence of Breast Cancer. *Sci Rep.* 2021, 11, 22242.

94. Packiam, V. T.; Lamm, D. L.; Barocas, D. A.; Trainer, A.; Fand, B.; Davis, R. L., 3rd; Clark, W.; Kroeger, M.; Dumbadze, I.; Chamie, K.; Kader, A. K.; Curran, D.; Gutheil, J.; Kuan, A.; Yeung, A. W.; Steinberg, G. D. An Open Label, Single-Arm, Phase II Multicenter Study of the Safety and Efficacy of CG0070 Oncolytic Vector Regimen in Patients with BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer: Interim Results. *Urol Oncol.* 2018, 36, 440-447.

95. Andtbacka, R. H. I.; Curti, B.; Daniels, G. A.; Hallmeyer, S.; Whitman, E. D.; Lutzky, J.; Spitler, L. E.; Zhou, K.; Bommareddy, P. K.; Grose, M.; Wang, M.; Wu, C.; Kaufman, H. L. Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients with Unresectable Melanoma. *J Clin Oncol.* 2021, 39, 3829-3838.

96. Toulmonde, M.; Cousin, S.; Kind, M.; Guegan, J. P.; Bessede, A.; Le Loarer, F.; Perret, R.; Cantarel, C.; Bellera, C.; Italiano, A. Randomized Phase 2 Trial of Intravenous Oncolytic Virus JX-594 Combined with Low-Dose Cyclophosphamide in Patients with Advanced Soft-Tissue Sarcoma. *J Hematol Oncol.* 2022, 15, 149.

97. Jonker, D. J.; Tang, P. A.; Kennecke, H.; Welch, S. A.; Cripps, M. C.; Asmis, T.; Chalchal, H.; Tomiak, A.; Lim, H.; Ko, Y. J.; Chen, E. X.; Alcindor, T.; Goffin, J. R.; Korpanty, G. J.; Feilotter, H.; Tsao, M. S.; Theis, A.; Tu, D.; Seymour, L. A Randomized Phase II Study of FOLFOX6/Bevacizumab with or without Pelareorep in Patients with Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial. *Clin Colorectal Cancer.* 2018, 17, 231-239.e7.

98. Bradbury, P. A.; Morris, D. G.; Nicholas, G.; Tu, D.; Tehfe, M.; Goffin, J. R.; Shepherd, F. A.; Gregg, R. W.; Rothenstein, J.; Lee, C.; Kuruvilla, S.; Keith, B. D.; Torri, V.; Blais, N.; Hao, D.; Korpanty, G. J.; Goss, G.; Melosky, B. L.; Mates, M.; Leighl, N.; Ayoub, J. P.; Sederias, J.; Feilotter, H.; Seymour, L.; Laurie, S. A. Canadian Cancer Trials Group (CCTG) IND211: A Randomized Trial of Pelareorep (Reolysin) in Patients with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer Receiving Standard Salvage Therapy. *Lung Cancer.* 2018, 120, 142-148.

99. Bernstein, V.; Ellard, S. L.; Dent, S. F.; Tu, D.; Mates, M.; Dhesy-Thind, S. K.; Panasci, L.; Gelmon, K. A.; Salim, M.; Song, X.; Clemons, M.; Ksienski, D.; Verma, S.; Simmons, C.; Lui, H.; Chi, K.; Feilotter, H.; Hagerman, L. J.; Seymour, L. A Randomized Phase II Study of Weekly Paclitaxel with or without Pelareorep in Patients with Metastatic Breast Cancer: Final Analysis of Canadian Cancer Trials Group IND.213. *Breast Cancer Res Treat.* 2018, 167, 485-493.

100. Hajda, J.; Leuchs, B.; Angelova, A. L.; Frehtman, V.; Rommelaere, J.; Mertens, M.; Pilz, M.; Kieser, M.; Krebs, O.; Dahm, M.; Huber, B.; Engeland, C. E.; Mavratzas, A.; Hohmann, N.; Schreiber, J.; Jäger, D.; Halama, N.; Sedlaczek, O.; Gaida, M. M.; Daniel, V.; Springfeld, C.; Ungerechts, G. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. *Clin Cancer Res.* 2021, 27, 5546-5556.

101. Schenk, E. L.; Mandrekar, S. J.; Dy, G. K.; Aubry, M. C.; Tan, A. D.; Dakhil, S. R.; Sachs, B. A.; Nieva, J. J.; Bertino, E.; Lee Hann, C.; Schild, S. E.; Wadsworth, T. W.; Adjei, A. A.; Molina, J. R. A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding After at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer Treatment Group (Alliance) N0923 Study. *J Thorac Oncol.* 2020, 15, 110-119.

102. Andtbacka, R. H. I.; Collichio, F.; Harrington, K. J.; Middleton, M. R.; Downey, G.; Öhrling, K.; Kaufman, H. L. Final Analyses of OPTiM: A Randomized Phase III Trial of Talimogene Laherparepvec versus Granulocyte-Macrophage Colony-Stimulating Factor in Unresectable Stage III-IV Melanoma. *J Immunother Cancer.* 2019, 7, 145.

103. Chesney, J.; Awasthi, S.; Curti, B.; Hutchins, L.; Linette, G.; Triozzi, P.; Tan, M. C. B.; Brown, R. E.; Nemunaitis, J.; Whitman, E.; Windham, C.; Lutzky, J.; Downey, G. F.; Batty, N.; Amatruda, T. Phase IIIb Safety Results from an Expanded-Access Protocol of Talimogene Laherparepvec for Patients with Unresected, Stage IIIB-IVM1c Melanoma. *Melanoma Res.* 2018, 28, 44-51.

104. Chung, Y. H.; Cai, H.; Steinmetz, N. F. Viral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications. *Adv Drug Deliv Rev.* 2020, 156, 214-235.

105. Steinmetz, N. F. Biological and Evolutionary Concepts for Nanoscale Engineering: Viruses as Natural Nanoparticles Have Great Potential for a Wide Range of Nanoscale Products. *EMBO Rep.* 2019, 20, e48806.

106. Bai, Y.; Hui, P.; Du, X.; Su, X. Updates to the Antitumor Mechanism of Oncolytic Virus. *Thoracic Cancer.* 2019, 10, 1031-1035.

107. Pesonen, S.; Kangasniemi, L.; Hemminki, A. Oncolytic Adenoviruses for the Treatment of Human Cancer: Focus on Translational and Clinical Data. *Mol Pharm.* 2011, 8, 12-28.

108. Barnard, A. S. Nanohazards: Knowledge Is Our First Defence. *Nat Mater.* 2006, 5, 245-248.

109. Ran, L.; Tan, X.; Li, Y.; Zhang, H.; Ma, R.; Ji, T.; Dong, W.; Tong, T.; Liu, Y.; Chen, D.; Yin, X.; Liang, X.; Tang, K.; Ma, J.; Zhang, Y.; Cao, X.; Hu, Z.; Qin, X.; Huang, B. Delivery of Oncolytic Adenovirus into the Nucleus of Tumorigenic Cells by Tumor Microparticles for Virotherapy. *Biomaterials.* 2016, 89, 56-66.

110. Hong, J.; Yun, C. O. Overcoming the Limitations of Locally Administered Oncolytic Virotherapy. *BMC Biomed Eng.* 2019, 1, 17.

111. Francini, N.; Cochrane, D.; Illingworth, S.; Purdie, L.; Mantovani, G.; Fisher, K.; Seymour, L. W.; Spain, S. G.; Alexander, C. Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies While Maintaining Biological Activity in Vitro and in Vivo. *Bioconjug Chem.* 2019, 30, 1244-1257.

112. Green, N. K.; Hale, A.; Cawood, R.; Illingworth, S.; Herbert, C.; Hermiston, T.; Subr, V.; Ulbrich, K.; van Rooijen, N.; Seymour, L. W.; Fisher, K. D. Tropism Ablation and Stealthing of Oncolytic Adenovirus Enhances Systemic Delivery to Tumors and Improves Virotherapy of Cancer. *Nanomedicine (Lond).* 2012, 7, 1683-1695.

113. Garofalo, M.; Bellato, F.; Magliocca, S.; Malfanti, A.; Kuryk, L.; Rinner, B.; Negro, S.; Salmaso, S.; Caliceti, P.; Mastrotto, F. Polymer Coated Oncolytic Adenovirus to Selectively Target Hepatocellular Carcinoma Cells. *Pharmaceutics.* 2021, 13, 949.

114. Semashko, V. V.; Pudovkin, M. S.; Cefalas, A. C.; Zelenikhin, P. V.; Gavriil, V. E.; Nizamutdinov, A. S.; Kollia, Z.; Ferraro, A. Tiny Rare-Earth Fluoride Nanoparticles Activate Tumor Cell Growth via Electrical Polar Interactions. *Nanoscale Res Lett.* 2018, 13, 370.

115. Choi, Y. J.; Kang, S. J.; Kim, Y. J.; Lim, Y. B.; Chung, H. W. Comparative Studies on the Genotoxicity and Cytotoxicity of Polymeric Gene Carriers Polyethylenimine (PEI) and Polyamidoamine (PAMAM) Dendrimer in Jurkat T-Cells. *Drug Chem Toxicol.* 2010, 33, 357-366.

116. Yang, C.; Cheng, W.; Teo, P. Y.; Engler, A. C.; Coady, D. J.; Hedrick, J. L.; Yang, Y. Y. Mitigated Cytotoxicity and Tremendously Enhanced Gene Transfection Efficiency of PEI through Facile One-Step Carbamate Modification. *Adv Healthc Mater.* 2013, 2, 1304-1308.

117. Aoyama, K.; Kuroda, S.; Morihiro, T.; Kanaya, N.; Kubota, T.; Kakiuchi, Y.; Kikuchi, S.; Nishizaki, M.; Kagawa, S.; Tazawa, H.; Fujiwara, T. Liposome-Encapsulated Plasmid DNA of Telomerase-Specific Oncolytic Adenovirus with Stealth Effect on the Immune System. *Sci Rep.* 2017, 7, 14177.

118. Record, M.; Silvente-Poirot, S.; Poirot, M.; Wakelam, M. J. O. Extracellular Vesicles: Lipids as Key Components of Their Biogenesis and Functions. *J Lipid Res.* 2018, 59, 1316-1324.

119. Huang, H.; Sun, M.; Liu, M.; Pan, S.; Liu, P.; Cheng, Z.; Li, J.; Xu, H.; Liu, F.; Pang, Z. Full Encapsulation of Oncolytic Virus Using Hybrid Erythrocyte-Liposome Membranes for Augmented Anti-Refractory Tumor Effectiveness. *Nano Today.* 2022, 47, 101671.

120. Wang, Y.; Huang, H.; Zou, H.; Tian, X.; Hu, J.; Qiu, P.; Hu, H.; Yan, G. Liposome Encapsulation of Oncolytic Virus M1 to Reduce Immunogenicity and Immune Clearance In Vivo. *Mol Pharm.* 2019, 16, 779-785.

121. Lin, Y.; Zhang, H.; Liang, J.; Li, K.; Zhu, W.; Fu, L.; Wang, F.; Zheng, X.; Shi, H.; Wu, S.; Xiao, X.; Chen, L.; Tang, L.; Yan, M.; Yang, X.; Tan, Y.; Qiu, P.; Huang, Y.; Yin, W.; Su, X.; Hu, H.; Hu, J.; Yan, G. Identification and Characterization of Alphavirus M1 as a Selective Oncolytic Virus Targeting ZAP-Defective Human Cancers. *Proc Natl Acad Sci U S A.* 2014, 111, E4504-4512.

122. Huang, C. H.; Dong, T.; Phung, A. T.; Shah, J. R.; Larson, C.; Sanchez, A. B.; Blair, S. L.; Oronsky, B.; Trogler, W. C.; Reid, T.; Kummel, A. Full Remission of CAR-Deficient Tumors by DOTAP-Folate Liposome Encapsulation of Adenovirus. *ACS Biomater Sci Eng.* 2022, 8, 5199-5209.

123. Garofalo, M.; Saari, H.; Somersalo, P.; Crescenti, D.; Kuryk, L.; Aksela, L.; Capasso, C.; Madetoja, M.; Koskinen, K.; Oksanen, T.; Mäkitie, A.; Jalasvuori, M.; Cerullo, V.; Ciana, P.; Yliperttula, M. Antitumor Effect of Oncolytic Virus and Paclitaxel Encapsulated in Extracellular Vesicles for Lung Cancer Treatment. *J Control Release.* 2018, 283, 223-234.

124. Garofalo, M.; Villa, A.; Rizzi, N.; Kuryk, L.; Rinner, B.; Cerullo, V.; Yliperttula, M.; Mazzaferro, V.; Ciana, P. Extracellular Vesicles Enhance the Targeted Delivery of Immunogenic Oncolytic Adenovirus and Paclitaxel in Immunocompetent Mice. *J Control Release.* 2019, 294, 165-175.

125. Chyzy, A.; Tomczykowa, M.; Plonska-Brzezinska, M. E. Hydrogels as Potential Nano-, Micro- and Macro-Scale Systems for Controlled Drug Delivery. *Materials (Basel).* 2020, 13, 188.

126. Le, T. M. D.; Jung, B. K.; Li, Y.; Duong, H. T. T.; Nguyen, T. L.; Hong, J. W.; Yun, C. O.; Lee, D. S. Physically Crosslinked Injectable Hydrogels for Long-Term Delivery of Oncolytic Adenoviruses for Cancer Treatment. *Biomater Sci.* 2019, 7, 4195-4207.

127. Deng, S.; Iscaro, A.; Zambito, G.; Mijiti, Y.; Minicucci, M.; Essand, M.; Lowik, C.; Muthana, M.; Censi, R.; Mezzanotte, L.; Di Martino, P. Development of a New Hyaluronic Acid Based Redox-Responsive Nanohydrogel for the Encapsulation of Oncolytic Viruses for Cancer Immunotherapy. *Nanomaterials (Basel).* 2021, 11, 144.

128. Hadryś, A.; Sochanik, A.; McFadden, G.; Jazowiecka-Rakus, J. Mesenchymal Stem Cells as Carriers for Systemic Delivery of Oncolytic Viruses. *Eur J Pharmacol.* 2020, 874, 172991.

129. Jazowiecka-Rakus, J.; Sochanik, A.; Rusin, A.; Hadryś, A.; Fidyk, W.; Villa, N.; Rahman, M. M.; Chmielik, E.; Franco, L. S.; McFadden, G. Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma. *Mol Ther Oncolytics.* 2020, 18, 335-350.

130. Fares, J.; Ahmed, A. U.; Ulasov, I. V.; Sonabend, A. M.; Miska, J.; Lee-Chang, C.; Balyasnikova, I. V.; Chandler, J. P.; Portnow, J.; Tate, M. C.; Kumthekar, P.; Lukas, R. V.; Grimm, S. A.; Adams, A. K.; Hébert, C. D.; Strong, T. V.; Amidei, C.; Arrieta, V. A.; Zannikou, M.; Horbinski, C.; Zhang, H.; Burdett, K. B.; Curiel, D. T.; Sachdev, S.; Aboody, K. S.; Stupp, R.; Lesniak, M. S. Neural Stem Cell Delivery of an Oncolytic Adenovirus in Newly Diagnosed Malignant Glioma: A First-in-Human, Phase 1, Dose-Escalation Trial. *Lancet Oncol.* 2021, 22, 1103-1114.

131. Mooney, R.; Majid, A. A.; Batalla-Covello, J.; Machado, D.; Liu, X.; Gonzaga, J.; Tirughana, R.; Hammad, M.; Lesniak, M. S.; Curiel, D. T.; Aboody, K. S. Enhanced Delivery of Oncolytic Adenovirus by Neural Stem Cells for Treatment of Metastatic Ovarian Cancer. *Mol Ther Oncolytics.* 2019, 12, 79-92.

132. Hammad, M.; Cornejo, Y. R.; Batalla-Covello, J.; Majid, A. A.; Burke, C.; Liu, Z.; Yuan, Y. C.; Li, M.; Dellinger, T. H.; Lu, J.; Chen, N. G.; Fong, Y.; Aboody, K. S.; Mooney, R. Neural Stem Cells Improve the Delivery of Oncolytic Chimeric Orthopoxvirus in a Metastatic Ovarian Cancer Model. *Mol Ther Oncolytics.* 2020, 18, 326-334.

133. Guo, Y.; Zhang, Z.; Xu, X.; Xu, Z.; Wang, S.; Huang, D.; Li, Y.; Mou, X.; Liu, F.; Xiang, C. Menstrual Blood-Derived Stem Cells as Delivery Vehicles for Oncolytic Adenovirus Virotherapy for Colorectal Cancer. *Stem Cells Dev.* 2019, 28, 882-896.

134. Santos, J.; Heiniö, C.; Quixabeira, D.; Zafar, S.; Clubb, J.; Pakola, S.; Cervera-Carrascon, V.; Havunen, R.; Kanerva, A.; Hemminki, A. Systemic Delivery of Oncolytic Adenovirus to Tumors Using Tumor-Infiltrating Lymphocytes as Carriers. *Cells.* 2021, 10, 978.

135. Liu, X.; Xu, J.; Yao, T.; Ding, J.; Li, S.; Su, R.; Zhang, H.; Li, H.; Yue, Q.; Gao, X. Cryo-Shocked Cancer Cells as an Oncolytic Adenovirus Reservoir for Glioblastoma Immunotherapy. *ACS Appl Mater Interfaces.* 2023, 15, 67-76.

136. Breitbach, C. J.; Arulanandam, R.; De Silva, N.; Thorne, S. H.; Patt, R.; Daneshmand, M.; Moon, A.; Ilkow, C.; Burke, J.; Hwang, T. H.; Heo, J.; Cho, M.; Chen, H.; Angarita, F. A.; Addison, C.; McCart, J. A.; Bell, J. C.; Kirn, D. H. Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans. *Cancer Res.* 2013, 73, 1265-1275.